Literature DB >> 17560735

Impact of radiation-induced xerostomia on quality of life after primary radiotherapy among patients with head and neck cancer.

Anke Petra Jellema1, Ben J Slotman, Patricia Doornaert, C René Leemans, Johannes A Langendijk.   

Abstract

PURPOSE: To investigate the impact of xerostomia on overall quality of life (QoL) outcome and related dimensions among head and neck cancer patients treated with primary radiotherapy. METHODS AND MATERIALS: A total of 288 patients with Stage I-IV disease without distant metastases were included. Late xerostomia according to the Radiation Therapy Oncology Group (RTOG-xerostomia) and QoL (European Organization for Research and Treatment of Cancer QLC-C30) were assessed at baseline and every 6th month from 6 months to 24 months after radiotherapy.
RESULTS: A significant association was found between RTOG-xerostomia and overall QoL outcome (effect size [ES] 0.07, p < 0.001). A significant relationship with global QoL, all functioning scales, and fatigue and insomnia was observed. A significant interaction term was present between RTOG-xerostomia and gender and between RTOG-xerostomia and age. In terms of gender, RTOG-xerostomia had a larger impact on overall QoL outcome in women (ES 0.13 for women vs. 0.07 for men). Furthermore, in women ES on individual scales were larger, and a marked worsening was observed with increasing RTOG-xerostomia. No different ES according to age was seen (ES 0.10 for 18-65 years vs. 0.08 for >65 years). An analysis of the impact of RTOG-xerostomia on overall QoL outcome over time showed an increase from 0.09 at 6 months to 0.22 at 24 months. With elapsing time, a worsening was found for these individual scales with increasing RTOG-xerostomia.
CONCLUSIONS: The results of this prospective study are the first to show a significant impact of radiation-induced xerostomia on QoL. Although the incidence of Grade > or =2 RTOG-xerostomia decreases with time, its impact on QoL increases. This finding emphasizes the importance of prevention of xerostomia.

Entities:  

Mesh:

Year:  2007        PMID: 17560735     DOI: 10.1016/j.ijrobp.2007.04.021

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  53 in total

Review 1.  Clinical management of salivary gland hypofunction and xerostomia in head-and-neck cancer patients: successes and barriers.

Authors:  Arjan Vissink; James B Mitchell; Bruce J Baum; Kirsten H Limesand; Siri Beier Jensen; Philip C Fox; Linda S Elting; Johannes A Langendijk; Robert P Coppes; Mary E Reyland
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-11-15       Impact factor: 7.038

2.  Parotid sparing and quality of life in long-term survivors of locally advanced head and neck cancer after intensity-modulated radiation therapy.

Authors:  Silke Tribius; Sven Haladyn; Henning Hanken; Chia-Jung Busch; Andreas Krüll; Cordula Petersen; Corinna Bergelt
Journal:  Strahlenther Onkol       Date:  2020-12-30       Impact factor: 3.621

Review 3.  Interobserver variation in parotid gland delineation: a study of its impact on intensity-modulated radiotherapy solutions with a systematic review of the literature.

Authors:  S W Loo; W M C Martin; P Smith; S Cherian; T W Roques
Journal:  Br J Radiol       Date:  2012-08       Impact factor: 3.039

Review 4.  Treatment of late sequelae after radiotherapy for head and neck cancer.

Authors:  Primož Strojan; Katherine A Hutcheson; Avraham Eisbruch; Jonathan J Beitler; Johannes A Langendijk; Anne W M Lee; June Corry; William M Mendenhall; Robert Smee; Alessandra Rinaldo; Alfio Ferlito
Journal:  Cancer Treat Rev       Date:  2017-07-18       Impact factor: 12.111

Review 5.  The humanistic burden of head and neck cancer: a systematic literature review.

Authors:  Erika Wissinger; Ingolf Griebsch; Juliane Lungershausen; Michael Byrnes; Karin Travers; Chris L Pashos
Journal:  Pharmacoeconomics       Date:  2014-12       Impact factor: 4.981

Review 6.  Intensive nutritional care for patients treated with radiotherapy in head and neck cancer: a randomized study and meta-analysis.

Authors:  Lise-Marie Roussel; Emmanuel Micault; Damien Peyronnet; David Blanchard; Séverine Guarnieri; Olivier Choussy; Bernard Géry; Arnaud Béquignon; Corinne Joubert; Jean-Jacques Parienti; Emmanuel Babin
Journal:  Eur Arch Otorhinolaryngol       Date:  2016-08-27       Impact factor: 2.503

7.  Can sparing of the superficial contralateral parotid lobe reduce xerostomia following radiotherapy for head and neck cancer?

Authors:  Daan Nevens; Sandra Nuyts
Journal:  Br J Radiol       Date:  2017-10-03       Impact factor: 3.039

8.  Xerostomia Quality of Life Scale (XeQoLS) questionnaire: validation of Italian version in head and neck cancer patients.

Authors:  Luciana Lastrucci; Silvia Bertocci; Vittorio Bini; Simona Borghesi; Roberta De Majo; Andrea Rampini; Pietro Giovanni Gennari; Paola Pernici
Journal:  Radiol Med       Date:  2017-08-31       Impact factor: 3.469

9.  Recurrent oropharyngeal cancer after organ preserving treatment: pattern of failure and survival.

Authors:  M de Ridder; Z A R Gouw; J J Sonke; A Navran; B Jasperse; J Heukelom; M E T Tesselaar; W M C Klop; M W M van den Brekel; Abrahim Al-Mamgani
Journal:  Eur Arch Otorhinolaryngol       Date:  2016-12-09       Impact factor: 2.503

10.  Loss of TRPM2 function protects against irradiation-induced salivary gland dysfunction.

Authors:  Xibao Liu; Ana Cotrim; Leyla Teos; Changyu Zheng; William Swaim; James Mitchell; Yasuo Mori; Indu Ambudkar
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.